0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Clonidine Potentiates the Growth Hormone (GH) Response to GH-Releasing Hormone in Norepinephrine Synthesis-Inhibited Rats: Evidence for an Alpha-2-Adrenergic Control of Hypothalamic Release of Somatostatin

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aim of this study was to investigate whether central α<sub>2</sub>-adrenergic pathways act, in rats, by inhibiting somatostatin (SS) release, as it has been postulated to occur in other species. The growth hormone (GH) responses to GH-releasing hormone (GRF, 3 µg/kg i.v.) or clonidine (CLO, 100 µg/kg, i.v.), either given alone or in combination, were tested in male rats in which norepinephrine synthesis had been previously blocked with the dopamine-β-hydroxylase inhibitor diethyldithiocarbamate (DDTC, 400 mg/kg i.p.). These experiments were also carried out in a control group of animals that had been given placebo (P) instead of DDTC. The GH responses to GRF in the presence of anti-SS serum given to other P and DDTC rats, allowed us to assess whether DDTC treatment had induced increased SS secretion. GH tests were carried out during spontaneous (P) or pharmacologically induced (DDTC) trough periods. Therefore, the mean ( ± SEM) GRF-induced GH peak was similarly low in both groups of rats (P: 66.5 ± 16.6 µg/1; DDTC: 58 ± 14 µg/1). The administration of anti-SS serum significantly (p < 0.01) increased these responses (P: 413 ± 22; DDTC: 695 ± 36; p < 0.01 vs. P). CLO administration elicited a maximal GH peak significantly higher (p < 0.05) in P (20.5 ± 3) than in DDTC rats (4.1 ± 2); however, the former was significantly lower than GH responses to GRF. The administration of CLO significantly potentiated (p < 0.01) the GRF-induced GH response; this was significantly higher (p < 0.01) in DDTC (575 ± 90) than in Prats (320 ± 50). Moreover, the former response was also significantly higher (p < 0.05) than that in P rats given anti-SS serum, although lower (p < 0.05) than that in DDTC animals which received this serum. In summary, α<sub>2</sub>-adrenergic agonism was able to potentiate the GH response to GRF in the presence of either a physiologically or pharmacologically increased somatostatinergic tone. The existence of such a synergism between CLO and GRF indicates that they elicit GH release through different mechanisms. Since the GH responses to CLO + GRF were similar to those induced by GRF in P or DDTC rats given anti-SS serum, it is likely that in rats, as in other species, α<sub>2</sub>-adrenergic pathways act in GH control by inhibiting the hypothalamic release of SS.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1993
          1993
          08 April 2008
          : 57
          : 6
          : 1155-1160
          Affiliations
          aDepartment of Physiology, Faculty of Medicine, University of Santiago de Compostela; bDepartment of Physiology, Faculty of Medicine, University of Madrid, Spain
          Article
          126482 Neuroendocrinology 1993;57:1155–1160
          10.1159/000126482
          7901787
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Original Paper

          Comments

          Comment on this article